1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Drugs In Development, 2022, provides an overview of the Endometriosis (Women's Health) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 13, 8, 19, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.
Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Endometriosis - Overview
- Endometriosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Endometriosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Endometriosis - Companies Involved in Therapeutics Development
- Endometriosis - Drug Profiles
- Endometriosis - Dormant Projects
- Endometriosis - Discontinued Products
- Endometriosis - Product Development Milestones
- Featured News & Press Releases
- Oct 26, 2022: Enteris BioPharma announces acceptance of abstract for oral presentation at ASRM 2022 Scientific Congress & Expo
- Jun 17, 2022: Myovant Sciences and Pfizer announce publication in The Lancet of phase 3 SPIRIT 1 and SPIRIT 2 studies of once-daily Relugolix combination therapy in women with endometriosis-associated pain
- Jun 14, 2022: Enteris BioPharma presents data from two clinical studies involving oral formulations of leuprolide at ENDO 2022 Annual Conference
- May 25, 2022: ObsEva presents clinical data on oral GnRH antagonist linzagolix at multiple congresses
- May 09, 2022: Ironwood Pharmaceuticals to present new IW-3300 data at Digestive Disease Week 2022
- May 09, 2022: FDA extends review period for Pfizer-Myovant’s sNDA for Myfembree
- Apr 28, 2022: BioInvent receives milestone payment from Bayer/Hope Medicine licensing agreement
- Apr 12, 2022: Enteris BioPharma announces acceptance of two abstracts for presentation at ENDO 2022 Annual Conference
- Apr 12, 2022: Myovant Sciences and Pfizer provide update on supplemental new drug application for MYFEMBREE for the management of moderate to severe pain associated with endometriosis
- Mar 22, 2022: ObsEva announces additional efficacy results for linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
- Jan 06, 2022: ObsEva announces positive topline results for Linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial in patients with moderate-to-severe endometriosis-associated pain
- Dec 10, 2021: ObsEva hosts symposium and presents clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
- Dec 02, 2021: ObsEva announces symposium and presentation of clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
- Oct 19, 2021: Myovant Sciences and Pfizer present data on Relugolix combination therapy from studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
- Oct 04, 2021: Enteris BioPharma announces successful completion of phase 1 clinical trial of optimized Peptelligence oral leuprolide
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Endometriosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Endometriosis - Pipeline by Abalone Bio Inc, 2022
- Endometriosis - Pipeline by Aptorum Group Ltd, 2022
- Endometriosis - Pipeline by Bayer AG, 2022
- Endometriosis - Pipeline by BCI Pharma SA, 2022
- Endometriosis - Pipeline by Bol Pharma, 2022
- Endometriosis - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
- Endometriosis - Pipeline by Context Therapeutics Inc, 2022
- Endometriosis - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Endometriosis - Pipeline by Egret Therapeutics Inc, 2022
- Endometriosis - Pipeline by Eikonoklastes Therapeutics Inc, 2022
- Endometriosis - Pipeline by ElexoPharm GmbH, 2022
- Endometriosis - Pipeline by Endomet Biosciences Inc, 2022
- Endometriosis - Pipeline by Enteris BioPharma Inc, 2022
- Endometriosis - Pipeline by Eurofarma Laboratorios SA, 2022
- Endometriosis - Pipeline by Evestra Inc, 2022
- Endometriosis - Pipeline by Evotec SE, 2022
- Endometriosis - Pipeline by Ferring International Center SA, 2022
- Endometriosis - Pipeline by Forendo Pharma Ltd, 2022
- Endometriosis - Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
- Endometriosis - Pipeline by Hangzhou Metai Pharmaceutical Technology Co Ltd, 2022
- Endometriosis - Pipeline by Hope Medicine Inc, 2022
- Endometriosis - Pipeline by Immunitor Inc, 2022
- Endometriosis - Pipeline by Insud Pharma, 2022
- Endometriosis - Pipeline by Ironwood Pharmaceuticals Inc, 2022
- Endometriosis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Endometriosis - Pipeline by Kissei Pharmaceutical Co Ltd, 2022
- Endometriosis - Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
- Endometriosis - Pipeline by Medibiofarma SL, 2022
- Endometriosis - Pipeline by Mithra Pharmaceuticals SA, 2022
- Endometriosis - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
- Endometriosis - Pipeline by Myovant Sciences Ltd, 2022
- Endometriosis - Pipeline by Navad Life Sciences Pte Ltd, 2022
- Endometriosis - Pipeline by Nippon Shinyaku Co Ltd, 2022
- Endometriosis - Pipeline by Predictive Therapeutics LLC, 2022
- Endometriosis - Pipeline by PregLem SA, 2022
- Endometriosis - Pipeline by SYNG Pharmaceuticals Inc, 2022
- Endometriosis - Pipeline by Synokem Pharmaceuticals Ltd, 2022
- Endometriosis - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Endometriosis - Pipeline by Temple Therapeutics BV, 2022
- Endometriosis - Pipeline by TiumBio Co Ltd, 2022
- Endometriosis - Pipeline by ValiRx Plc, 2022
- Endometriosis - Pipeline by Viramal Ltd, 2022
- Endometriosis - Pipeline by Xbrane Biopharma AB, 2022
- Endometriosis - Dormant Projects, 2022
- Endometriosis - Dormant Projects, 2022 (Contd..1)
- Endometriosis - Dormant Projects, 2022 (Contd..2)
- Endometriosis - Dormant Projects, 2022 (Contd..3)
- Endometriosis - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Endometriosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abalone Bio Inc
- Aptorum Group Ltd
- Bayer AG
- BCI Pharma SA
- Bol Pharma
- Chugai Pharmaceutical Co Ltd
- Context Therapeutics Inc
- Daewoong Pharmaceutical Co Ltd
- Egret Therapeutics Inc
- Eikonoklastes Therapeutics Inc
- ElexoPharm GmbH
- Endomet Biosciences Inc
- Enteris BioPharma Inc
- Eurofarma Laboratorios SA
- Evestra Inc
- Evotec SE
- Ferring International Center SA
- Forendo Pharma Ltd
- GeneScience Pharmaceuticals Co Ltd
- Hangzhou Metai Pharmaceutical Technology Co Ltd
- Hope Medicine Inc
- Immunitor Inc
- Insud Pharma
- Ironwood Pharmaceuticals Inc
- Jiangsu Hengrui Medicine Co Ltd
- Kissei Pharmaceutical Co Ltd
- Livzon Pharmaceutical Group Co Ltd
- Medibiofarma SL
- Mithra Pharmaceuticals SA
- Mitsubishi Tanabe Pharma Corp
- Myovant Sciences Ltd
- Navad Life Sciences Pte Ltd
- Nippon Shinyaku Co Ltd
- Predictive Therapeutics LLC
- PregLem SA
- SYNG Pharmaceuticals Inc
- Synokem Pharmaceuticals Ltd
- Takeda Pharmaceutical Co Ltd
- Temple Therapeutics BV
- TiumBio Co Ltd
- ValiRx Plc
- Viramal Ltd
- Xbrane Biopharma AB
